Trazodone 5mg + Psilocybin for depressive disorder, treatment-resistant

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 7 Oct 2025: Trial registered, NCT07210112
  2. 30 Jun 2026: Trial started, NCT07210112

The trials

NCT07210112: Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ)

State
Under way
Phase
Phase 2
People
112 planned
Started
30 Jun 2026
Primary completion
31 Dec 2029
Arms
Group 2
Results
None posted
  1. 7 Oct 2025: Trial registered
  2. 30 Jun 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.